With the burgeoning interest in groundbreaking treatments for glucose dysregulation and excess fat reduction, a direct assessment of the GLP-1/GIP agonist and Peggo has become essential. While both medications function through akin mechanisms – affecting glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide sites – key variat